PointState Capital’s ADMA Biologics ADMA Stock Holding History

PointState Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-203,158	Closed	-$1.64M	–	91
2015 Q4	$1.64M	Hold	203,158	–	–	0.04%	81
2015 Q3	$1.7M	Hold	203,158	–	–	0.05%	78
2015 Q2	$1.88M	Hold	203,158	–	–	0.02%	126
2015 Q1	$1.99M	Buy	+203,158	New	+$2.05M	0.03%	109

Other funds holding ADMA

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

WMSA

Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

PointState Capital's ADMA Position: Q1 2016 in Review

PointState Capital sold out of ADMA Biologics (ADMA) in Q1 2016, closing a stake of 203,158 shares — an estimated $1.64M sold.

PointState Capital first reported a position in ADMA in Q1 2015 and held it in 4 quarters. The position peaked at $1.99M in Q1 2015. 23 funds tracked by Wall St. Rank hold ADMA as of Q1 2016.

PointState Capital reported no remaining ADMA Biologics position as of Q1 2016 after selling out during the quarter.
PointState Capital sold 203,158 ADMA Biologics shares in Q1 2016, an estimated $1.64M.
PointState Capital first reported a position in ADMA Biologics in Q1 2015 and held it in 4 quarters.
PointState Capital's ADMA Biologics position peaked at $1.99M in Q1 2015.
23 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2016.

Based on PointState Capital's 13F filing for Q1 2016, filed 16 May 2016.